RT Journal Article
SR Electronic
T1 Characterization of the humoral immune response to BNT162b2 in elderly residents of long-term care facilities five to seven months after vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.09.21266110
DO 10.1101/2021.11.09.21266110
A1 Delbrück, Marla
A1 Hoehl, Sebastian
A1 Toptan, Tuna
A1 Schenk, Barbara
A1 Grikscheit, Katharina
A1 Metzler, Melinda
A1 Herrmann, Eva
A1 Ciesek, Sandra
YR 2021
UL http://medrxiv.org/content/early/2021/11/10/2021.11.09.21266110.abstract
AB The elderly residing in long-term care facilities (LTCFs) are a group at high risk for COVID-19. Hence, monitoring of the vaccine-based immunity has a pivotal role in identifying strategies to provide optimal protection in this population. We examined the immune response to the mRNA vaccine BNT162b2 against COVID-19 five to seven months after completing a two-dose regimen.We determined significantly lower anti-SARS-CoV-2 antibody titers in 298 SARS-CoV-2 naïve residents who were at least 75 years of age (mean 51.60 BAU/ml) (median age 87 years, range 75 to 101 years) when compared to health care workers (HCWs) aged 18 to 70 years (mean 156.99 BAU/ml, p < 0.001). Of the SARS-CoV-2 naïve residents, 29 had detectable neutralizing antibodies against the Delta variant (9.5%), and 14 of those (48.3%) only had a borderline titer of 1:10. Of 114 HCWs, 36 (31.6%) had detectable neutralizing antibodies. In a group of 14 elderly residents who had had a PCR-confirmed breakthrough infection, the mean antibody titer was significantly higher than in the other two groups (3199.65 BAU/mL) (p < 0.001), and 12 (85.7%) had detectable neutralizing antibodies against the Delta variant.Our data demonstrate that 90.5% of elderly residents of LTCFs had no detectable neutralization-competent antibodies against the dominant Delta variant five to seven months after vaccination, and that neutralizing antibody titers were restored following a break-through infection. Our results suggest that both residents and health care workers in LTCFs would benefit from a booster vaccine six months after completing the two-dose schedule or earlier.Competing Interest StatementS.C. received honorarium for serving on a clinical advisory board for BioNTech.Funding StatementThe study was commissioned and funded by the Hessian Ministry of Social Issues and Integration.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol has been approved by the ethics board of the University Hospital Frankfurt (No. 20-864).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript